Seven gut neuropeptides are dysregulated in Parkinson's disease and may drive gut-brain disease progression
Dysregulation of 7 gut neuropeptides (VIP, NPY, CGRP, ghrelin, CCK, GLP-1, substance P) in the enteric nervous system may drive Parkinson's disease through gut-brain axis alterations linked to α-synuclein aggregation and neuroinflammation.
Quick Facts
What This Study Found
7 dysregulated gut neuropeptides in PD: VIP, NPY, CGRP, ghrelin, CCK, GLP-1, substance P. GI symptoms precede motor symptoms by up to 20 years. α-Synuclein aggregates in GI tract. Gut neuropeptides modulate: barrier function, immune response, gut-brain signaling. Underexplored research area.
Key Numbers
How They Did This
Narrative review of gut neuropeptide roles in PD pathogenesis, covering microbial metabolite and immune influences on neuropeptide signaling.
Why This Research Matters
PD may begin in the gut years before brain symptoms. Understanding how gut neuropeptides contribute to disease initiation and progression could enable early detection and intervention.
The Bigger Picture
If PD starts in the gut through neuropeptide dysregulation, targeting these peptides could prevent or slow disease progression before brain damage occurs—a paradigm shift from treating symptoms to preventing neurodegeneration.
What This Study Doesn't Tell Us
Narrative review. Mostly animal model evidence. Causation vs correlation unclear. Human gut neuropeptide data in PD limited.
Questions This Raises
- ?Could gut neuropeptide levels serve as early PD biomarkers?
- ?Would GLP-1 drugs protect against PD through gut neuropeptide modulation?
- ?Is α-synuclein aggregation in the gut driven by specific neuropeptide dysregulation?
Trust & Context
- Key Stat:
- 7 gut peptides dysregulated in PD GI neuropeptide dysregulation may drive Parkinson's disease through the gut-brain axis, with symptoms preceding motor diagnosis by up to 20 years
- Evidence Grade:
- Narrative review synthesizing animal and human evidence. Identifies important but underexplored research direction.
- Study Age:
- Published in 2025.
- Original Title:
- Gut neuropeptide involvement in Parkinson's disease.
- Published In:
- American journal of physiology. Gastrointestinal and liver physiology, 328(6), G716-G733 (2025)
- Database ID:
- RPEP-13789
Evidence Hierarchy
Frequently Asked Questions
Does Parkinson's disease start in the gut?
Growing evidence suggests it may. Gut symptoms often appear 20 years before Parkinson's is diagnosed, and the toxic protein (α-synuclein) that causes PD has been found in the GI tract. This review identifies 7 gut neuropeptides that are disrupted in PD and may facilitate disease spread from gut to brain.
Could testing gut hormones detect Parkinson's early?
Potentially. If specific gut neuropeptide patterns (VIP, NPY, CGRP, ghrelin, CCK, GLP-1, substance P) are altered years before motor symptoms, they could serve as early diagnostic biomarkers. GLP-1 drugs, already showing PD neuroprotection, might also work partly through restoring gut neuropeptide balance.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13789APA
Templeton, Hayley N; Tobet, Stuart A; Schwerdtfeger, Luke A. (2025). Gut neuropeptide involvement in Parkinson's disease.. American journal of physiology. Gastrointestinal and liver physiology, 328(6), G716-G733. https://doi.org/10.1152/ajpgi.00383.2024
MLA
Templeton, Hayley N, et al. "Gut neuropeptide involvement in Parkinson's disease.." American journal of physiology. Gastrointestinal and liver physiology, 2025. https://doi.org/10.1152/ajpgi.00383.2024
RethinkPeptides
RethinkPeptides Research Database. "Gut neuropeptide involvement in Parkinson's disease." RPEP-13789. Retrieved from https://rethinkpeptides.com/research/templeton-2025-gut-neuropeptide-involvement-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.